viernes, 17 de octubre de 2014

Press Announcements > FDA approves Ofev to treat idiopathic pulmonary fibrosis

Press Announcements > FDA approves Ofev to treat idiopathic pulmonary fibrosis

FDA approves Ofev to treat idiopathic pulmonary fibrosis

For Immediate Release

October 15, 2014


The U.S. Food and Drug Administration today approved Ofev 
(nintedanib) for the treatment of 
idiopathic pulmonary fibrosis (IPF).
Idiopathic pulmonary fibrosis is a condition in which the lungs
become progressively scarred over time. As a result, patients with
IPF experience shortness of breath, cough, and have difficulty
participating in everyday physical activities. Current treatments for
IPF include oxygen therapy, pulmonary rehabilitation, and
lung transplant.
“Today’s Ofev approval expands the available treatment options
for patients with idiopathic pulmonary fibrosis, a serious, chronic
condition,” said Mary H. Parks, M.D., deputy director of the Office of
Drug Evaluation II in the FDA’s Center for Drug Evaluation and Research. 
“Providing health care professionals and patients with additional 
treatment options helps enable appropriate care decisions based on 
a patient’s need.”
The FDA granted Ofev fast track, priority review, orphan product,
and breakthrough designations. Ofev is being approved ahead of
the product’s prescription drug user fee goal date of Jan. 2, 2015,
the date the agency was scheduled to complete the review of the
drug application.
Ofev is a kinase inhibitor that blocks multiple pathways that may be
involved in the scarring of lung tissue. Its safety and effectiveness
were established in three clinical trials of 1,231 patients with IPF.
The decline in forced vital capacity – the amount of air which can be
forcibly exhaled from the lungs after taking the deepest breath
possible – was significantly reduced in patients receiving Ofev
compared to patients receiving placebo.
Ofev is not recommended for patients who have moderate to
severe liver problems. Ofev can cause birth defects or death to an
unborn baby. Women should not become pregnant while taking Ofev.
Women who are able to get pregnant should use adequate contraception
during and for at least three months after the last dose of Ofev.
The most common side effects of Ofev are diarrhea, nausea, abdominal pain, vomiting, liver enzyme elevation, decreased appetite, headache, decreased weight, and high blood pressure.
The FDA also today approved Esbriet (pirfenidone) for the treatment of IPF.
Ofev is distributed by Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut.
The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

No hay comentarios:

Publicar un comentario